Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial
<p><strong>Background</p></strong> Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a proinflammatory cytokine overproduced in several inflammatory and autoimmune diseases, including axial spondyloarthritis. Namilumab is a human IgG1 monoclonal anti-GM-CSF antibod...
Main Authors: | Worth, C, Al-Mossawi, MH, MacDonald, J, Fisher, BA, Chan, A, Sengupta, R, Packham, J, Gaffney, K, Gullick, N, Cook, JA, Corn, TH, Teh, J, Machado, PM, Taylor, PC, Bowness, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2024
|
Similar Items
-
A first in disease phase 2A trial of granulocyte monocyte colony stimulating factor neutralisation for axial spondyloarthritis (NAMASTE study)
by: Al-Mossawi, MH, et al.
Published: (2021) -
Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial
by: Worth, C, et al.
Published: (2024) -
Novel therapeutic targets in axial spondyloarthritis
by: Worth, C, et al.
Published: (2018) -
„CORONA VIRUS HANDLING – ‘NAMASTE’“
by: Sande Smiljanov
Published: (2022-06-01) -
STRATEGI PROMOSI EVENT NAMASTE FESTIVAL
by: Arie Wibowo
Published: (2015-11-01)